4ZYF image
Deposition Date 2015-05-21
Release Date 2015-07-29
Last Version Date 2024-01-10
Entry Detail
PDB ID:
4ZYF
Keywords:
CELL CYCLE
Title:
Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors: Hdm2 (MDM2) complexed with NVP-CGM097
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Escherichia coli
Method Details:
Experimental Method:
X-RAY DIFFRACTION
Resolution:
1.80 Å
R-Value Free:
0.23
R-Value Work:
0.22
R-Value Observed:
0.22
Space Group:
P 61 2 2
4ZYF validation report
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:E3 ubiquitin-protein ligase Mdm2
Gene (Uniprot):MDM2
Chain IDs:A
Chain Length:96
Number of Molecules:1
Biological Source:Homo sapiens
UniProt ID:Q00987 Pfam ID:PF02201 EC:2.3.2.27
Ligand Molecules
4T4
CL
Primary Citation
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.
J.Med.Chem. 58 6348 6358 (2015)
PMID: 26181851 DOI: 10.1021/acs.jmedchem.5b00810

Abstact

As a result of our efforts to discover novel p53:MDM2 protein-protein interaction inhibitors useful for treating cancer, the potent and selective MDM2 inhibitor NVP-CGM097 (1) with an excellent in vivo profile was selected as a clinical candidate and is currently in phase 1 clinical development. This article provides an overview of the discovery of this new clinical p53:MDM2 inhibitor. The following aspects are addressed: mechanism of action, scientific rationale, binding mode, medicinal chemistry, pharmacokinetic and pharmacodynamic properties, and in vivo pharmacology/toxicology in preclinical species.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
4ZYC
4DIJ
4OQ3
Feedback Form
Name
Email
Institute
Feedback